Proteocyte Diagnostics Inc.
Proteocyte commercializes a novel molecular diagnostic test that accurately detects oral cancer before it happens to save lives and reduce health care costs.
Proteocyte commercializes Straticyte a molecular diagnostic test that accurately detects oral cancer before it happens to save lives and save health care costs.
Straticyte predicts the probability of a precancerous lesion becoming cancer in the next 5 years based on the presence of biomarkers present in the lesions.
There are 3 million precancerous lesions each year, offering an addressable market of $900 million in the more developed world.